Baidu
map

Lancet neurology:帕金森病前驱症状案例对照研究

2014-12-20 MedSci译 MedSci原创

研究背景: 帕金森病起病隐匿,往往患者出现典型的运动障碍特征时才得以确诊。在疾病的早期阶段,患者可能出现一些非运动性和运动性前驱症状。本研究的目的即在于探讨帕金森病与首次出现前驱症状之间的关联性,并确定前驱症状的时间线,这有利于疾病的早期诊断。 研究方法: 研究人员在Health Improvement Network UK保健数据库,收集自1996年1月1日至2012年12月3

研究背景: 帕金森病起病隐匿,往往患者出现典型的运动障碍特征时才得以确诊。在疾病的早期阶段,患者可能出现一些非运动性和运动性前驱症状。本研究的目的即在于探讨帕金森病与首次出现前驱症状之间的关联性,并确定前驱症状的时间线,这有利于疾病的早期诊断。 研究方法: 研究人员在Health Improvement Network UK保健数据库,收集自1996年1月1日至2012年12月31日期间首次确诊帕金森病的人群数据和未患帕金森疾病的人群数据。研究人员分析患者确诊帕金森病前驱症状,包括运动功能(震颤、僵直、平衡障碍、颈部疼痛或僵硬、肩部疼痛或僵硬)、自主神经系统功能(便秘、低血压、勃起功能障碍、泌尿功能障碍、头晕)、神经精神障碍(记忆、迟发性焦虑或抑郁,认知能力下降和冷漠),以及附加表征(疲劳、失眠、嗅觉丧失、唾液分泌过多、快速眼动睡眠行为障碍)。研究人员主要描述了在每1000人年数中,发生率大于1%的前驱症状,并分别在帕金森病人群和对照人群中统计了疾病诊断前2年、5年、10年的前驱症状风险率。 研究结果: Table 1. Characteristics of patients with

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1775283, encodeId=be571e7528322, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sun Jun 07 03:06:00 CST 2015, time=2015-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999479, encodeId=714619994e9a4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Oct 25 23:06:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32622, encodeId=6b50326227f, content=想知道更详细的。, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31901632235, createdName=1dd8eb19m15(暂无匿称), createdTime=Mon Jul 13 21:42:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827953, encodeId=4b95182e95365, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Aug 05 20:06:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054255, encodeId=c7a620542553a, content=<a href='/topic/show?id=4fda3269ed6' target=_blank style='color:#2F92EE;'>#前驱症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32697, encryptionId=4fda3269ed6, topicName=前驱症状)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Sun Oct 25 10:06:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13887, encodeId=4fd31388ecf, content=很不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:08:00 CST 2015, time=2015-01-10, status=1, ipAttribution=)]
    2015-06-07 amyloid
  2. [GetPortalCommentsPageByObjectIdResponse(id=1775283, encodeId=be571e7528322, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sun Jun 07 03:06:00 CST 2015, time=2015-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999479, encodeId=714619994e9a4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Oct 25 23:06:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32622, encodeId=6b50326227f, content=想知道更详细的。, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31901632235, createdName=1dd8eb19m15(暂无匿称), createdTime=Mon Jul 13 21:42:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827953, encodeId=4b95182e95365, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Aug 05 20:06:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054255, encodeId=c7a620542553a, content=<a href='/topic/show?id=4fda3269ed6' target=_blank style='color:#2F92EE;'>#前驱症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32697, encryptionId=4fda3269ed6, topicName=前驱症状)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Sun Oct 25 10:06:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13887, encodeId=4fd31388ecf, content=很不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:08:00 CST 2015, time=2015-01-10, status=1, ipAttribution=)]
    2015-10-25 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1775283, encodeId=be571e7528322, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sun Jun 07 03:06:00 CST 2015, time=2015-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999479, encodeId=714619994e9a4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Oct 25 23:06:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32622, encodeId=6b50326227f, content=想知道更详细的。, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31901632235, createdName=1dd8eb19m15(暂无匿称), createdTime=Mon Jul 13 21:42:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827953, encodeId=4b95182e95365, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Aug 05 20:06:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054255, encodeId=c7a620542553a, content=<a href='/topic/show?id=4fda3269ed6' target=_blank style='color:#2F92EE;'>#前驱症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32697, encryptionId=4fda3269ed6, topicName=前驱症状)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Sun Oct 25 10:06:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13887, encodeId=4fd31388ecf, content=很不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:08:00 CST 2015, time=2015-01-10, status=1, ipAttribution=)]
    2015-07-13 1dd8eb19m15(暂无匿称)

    想知道更详细的。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1775283, encodeId=be571e7528322, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sun Jun 07 03:06:00 CST 2015, time=2015-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999479, encodeId=714619994e9a4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Oct 25 23:06:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32622, encodeId=6b50326227f, content=想知道更详细的。, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31901632235, createdName=1dd8eb19m15(暂无匿称), createdTime=Mon Jul 13 21:42:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827953, encodeId=4b95182e95365, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Aug 05 20:06:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054255, encodeId=c7a620542553a, content=<a href='/topic/show?id=4fda3269ed6' target=_blank style='color:#2F92EE;'>#前驱症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32697, encryptionId=4fda3269ed6, topicName=前驱症状)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Sun Oct 25 10:06:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13887, encodeId=4fd31388ecf, content=很不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:08:00 CST 2015, time=2015-01-10, status=1, ipAttribution=)]
    2015-08-05 howi
  5. [GetPortalCommentsPageByObjectIdResponse(id=1775283, encodeId=be571e7528322, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sun Jun 07 03:06:00 CST 2015, time=2015-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999479, encodeId=714619994e9a4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Oct 25 23:06:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32622, encodeId=6b50326227f, content=想知道更详细的。, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31901632235, createdName=1dd8eb19m15(暂无匿称), createdTime=Mon Jul 13 21:42:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827953, encodeId=4b95182e95365, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Aug 05 20:06:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054255, encodeId=c7a620542553a, content=<a href='/topic/show?id=4fda3269ed6' target=_blank style='color:#2F92EE;'>#前驱症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32697, encryptionId=4fda3269ed6, topicName=前驱症状)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Sun Oct 25 10:06:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13887, encodeId=4fd31388ecf, content=很不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:08:00 CST 2015, time=2015-01-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1775283, encodeId=be571e7528322, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sun Jun 07 03:06:00 CST 2015, time=2015-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999479, encodeId=714619994e9a4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Oct 25 23:06:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32622, encodeId=6b50326227f, content=想知道更详细的。, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31901632235, createdName=1dd8eb19m15(暂无匿称), createdTime=Mon Jul 13 21:42:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827953, encodeId=4b95182e95365, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Aug 05 20:06:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054255, encodeId=c7a620542553a, content=<a href='/topic/show?id=4fda3269ed6' target=_blank style='color:#2F92EE;'>#前驱症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32697, encryptionId=4fda3269ed6, topicName=前驱症状)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Sun Oct 25 10:06:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13887, encodeId=4fd31388ecf, content=很不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:08:00 CST 2015, time=2015-01-10, status=1, ipAttribution=)]
    2015-01-10 zczcz6655

    很不错的文章

    0

相关资讯

BMC Complement Altern Med:蜂毒针灸可能用于帕金森病的治疗

一项新的小型研究结果显示针灸和蜂毒针灸都可改善帕金森病患者的症状。这项研究发布于最近国际帕金森和运动障碍学会(MDS)第18届国际帕金森和运动障碍大会上。 该研究作者,韩国汉城Gangdong 的Kyung Hee 大学医院卒中和神经疾病中心的Seong-Uk Park博士在Medscape医学新闻中解释说,研究表明针灸或可通过增加多巴胺的外排和逆转化使帕金森病患者获益。研究也已显示它可提高L-多

JAMA Neurol:帕金森病患者冻结步态与生活质量的研究

近期,法国图卢兹大学的Olivier Rascol教授等开展了一项关于帕金森病(PD)患者冻结步态(freezing of gait, FOG)发生率、影响因素以对患者生活质量影响的研究,该研究的结果发表于2014年5月的JAMA neurology杂志。冻结步态是帕金森病药物治疗时较为常见的一种不良反应,表现为行走过程中(特别是起始和转身时)突然发生的步态停滞,在症状波动的缓解期(“开”期)和(

Lancet:治疗帕金森病——左旋多巴理想!

近来,针对帕金森病治疗的一项大型、长期的研究试验显示,确诊为帕金森病的患者,坚持长期服用左旋多巴后活动能力与生活质量大大改善,疗效明显优于多巴胺受体激动剂(DA)和单胺氧化酶抑制剂(MAOBI),这一重大研究成果发表在2014年6月11日《柳叶刀》杂志上。【原文下载】 该研究纳入1620名帕金森病早期患者,随机分配到左旋多巴治疗组和非左旋多巴治疗组(DA或MAOBI),跟踪随访7年,分别对他

GGI:茶和咖啡因降低帕金森病风险

中国学者研究发现,茶和咖啡因摄入降低帕金森疾病(PD)风险,且呈线性剂量关系,而咖啡摄入量约为3杯/天时,其保护作用达到最大值。还需进行深入研究以确认结果。论文发表于《国际老年病学与老年学》杂志[Geriatr Gerontol Int, 2014,14: 430–439] 该研究具体设计如下: 目的:对PD风险和咖啡、茶以及咖啡因摄入量之间的剂量反应进行meta分析

Neurology:帕金森病的诊断准确性研究

神经内科医生因工作性质须具备较为娴熟的临床技能。由于诊断工具有限,这些技能在运动障碍疾病的临床实践中尤为重要。1817年James Parkinson描述了这种以他名字命名的疾病的临床特征。1913年,F. Lewy报告了神经包涵体,即著名的路易小体。1919年,Tretiakoff描述了帕金森病(PD)黑质神经元的丢失。路易体性帕金森病,特发性帕金森病和帕金森病这些术语对于临床神经内科医生来说都

Neurology:帕金森病患者的痴呆风险预测

为研究帕金森病患者发生痴呆的早期标志性征象,来自加拿大蒙特利尔麦吉尔大学的Postuma博士科研团队展开了相关研究,研究成果于近日发表在最新一期Neurology杂志上。 本试验纳入80名不伴痴呆的帕金森病患者,全面评估他们的自主神经活动、睡眠、精神状态、视觉、嗅觉和运动情况。跟踪随访4.4年后,对他们进行痴呆相关症状的评估。本研究采用logistic回归法调整了病程长短、随访持续时间、

Baidu
map
Baidu
map
Baidu
map